Ionis Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

04.11.24	Ionis Announces FDA Acceptance Of NDA For Donidalorsen For Prophylactic Treatment Of HAE (RTTNews)
21.10.24	AstraZeneca : Wainzua Recommended By CHMP For EU Approval In Hereditary Transthyretin Amyloidosis (RTTNews)
01.10.24	Ionis Pharma Says FDA Grants Fast Track Designation For Zilganersen To Treat Alexander Disease (RTTNews)
22.07.24	Ionis Pharma Announces Positive Results From Phase 1/2 Study Of ION582 In Angelman Syndrome (RTTNews)
18.06.24	Ionis: Otsuka Obtains Rights Across Asia-Pacific Region For Donidalorsen - Quick Facts (RTTNews)
31.05.24	Biogen : EU Approves Qalsody To Treat Rare, Genetic Form Of Amyotrophic Lateral Sclerosis (RTTNews)
16.05.24	Ionis Reports Positive Topline Data From The HALOS Phase 1/2a Study In Angelman Syndrome (RTTNews)
13.03.24	Ionis Pharma's Phase 2 Study Of ION224 In MASH Meets Primary Goal (RTTNews)
21.02.24	IONIS PHARMA Q4 Loss Narrows, Beats Estimates - Update (RTTNews)
15.02.24	Ionis' Olezarsen Receives FDA Orphan Drug Designation (RTTNews)
08.02.24	Ionis Says Eplontersen Got Fast Track Status To Treat Transthyretin-mediated Amyloid Cardiomyopathy (RTTNews)
22.01.24	Ionis Pharma's Phase 3 OASIS-HAE Study Of Donidalorsen In Hereditary Angioedema Meets Main Goal (RTTNews)
22.12.23	AZN :FDA Oks Wainua For Treatment Of Polyneuropathy Of Hereditary Transthyretin-Mediated Amyloidosis (RTTNews)
22.12.23	WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (PR Newswire)
20.12.23	Ionis to present at 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
18.12.23	Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema (PR Newswire)
14.12.23	Ionis announces the appointment of Michael Yang to Board of Directors (PR Newswire)
30.11.23	Biotech Stocks Facing FDA Decision In December 2023 (RTTNews)
11.11.23	Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome (PR Newswire)
09.11.23	Ionis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedema (PR Newswire)
03.11.23	Ionis to present at upcoming investor conferences (PR Newswire)
02.11.23	Ionis reports third quarter 2023 financial results (PR Newswire)
19.10.23	Ionis to hold third quarter 2023 financial results webcast (PR Newswire)
04.10.23	Ionis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercialization (PR Newswire)
28.09.23	Eplontersen Phase 3 results published in JAMA show consistent and sustained benefit (PR Newswire)
27.09.23	Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease (PR Newswire)
26.09.23	Ionis Reports Positive Results From Phase 3 Study Of Olezarsen In Familial Chylomicronemia Syndrome (RTTNews)
26.09.23	Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome (PR Newswire)
12.09.23	Ionis to host investor and analyst day event (PR Newswire)
30.08.23	Ionis to present at upcoming investor conferences (PR Newswire)
09.08.23	Ionis reports second quarter 2023 financial results (PR Newswire)
03.08.23	Ionis enters collaboration to advance next generation program targeting Lp(a) for cardiovascular disease (PR Newswire)
31.07.23	Ionis completes enrollment in landmark Phase 3 CARDIO-TTRansform study in patients with TTR-mediated amyloid cardiomyopathy (PR Newswire)
28.07.23	Ionis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America (PR Newswire)
26.07.23	Ionis to hold second quarter 2023 financial results webcast (PR Newswire)
10.07.23	Eplontersen continued to show improvement in ATTRv-PN through 85 weeks (PR Newswire)
05.07.23	Ionis to present at upcoming investor conference (PR Newswire)
30.06.23	New data highlight potential benefit of SPINRAZA® (nusinersen) in infants and toddlers with unmet medical needs after gene therapy (PR Newswire)
08.06.23	Ionis prices private placement of convertible senior notes (PR Newswire)
06.06.23	Ionis announces proposed private placement of convertible notes (PR Newswire)
01.06.23	Ionis announces positive donidalorsen late-stage clinical progress in HAE (PR Newswire)
10.05.23	Ionis to host 2023 virtual Annual Meeting of Stockholders (PR Newswire)
09.05.23	Ionis to present at upcoming investor conferences (PR Newswire)
26.04.23	FDA Grants Accelerated Approval For Biogen's ALS Drug (RTTNews)
26.04.23	FDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS (PR Newswire)
24.04.23	Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks (PR Newswire)
20.04.23	Ionis to hold first quarter 2023 financial results webcast (PR Newswire)
29.03.23	Biogen: BIIB080 Phase 1b Study Shows Reduction Of Tau PET Across Brain Regions (RTTNews)
29.03.23	New data presented at AD/PD™2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's disease (PR Newswire)
28.03.23	Ionis to present at upcoming investor conferences (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

15.11.24		Schwacher Handel in New York: NASDAQ Composite verbucht zum Handelsende Abschläge
10.09.24		Dienstagshandel in New York: NASDAQ Composite zum Ende des Dienstagshandels auf grünem Terrain
10.09.24		Pluszeichen in New York: Anleger lassen NASDAQ Composite am Nachmittag steigen
10.09.24		Schwacher Handel: So entwickelt sich der NASDAQ Composite aktuell
10.09.24		Freundlicher Handel: NASDAQ Composite startet im Plus
30.08.24		Börse New York in Grün: NASDAQ Composite beendet die Sitzung im Plus
27.08.24		Optimismus in New York: NASDAQ Composite liegt schlussendlich im Plus
22.07.24		Freundlicher Handel in New York: NASDAQ Composite notiert zum Handelsstart im Plus

15.11.24

Schwacher Handel in New York: NASDAQ Composite verbucht zum Handelsende Abschläge

10.09.24

Dienstagshandel in New York: NASDAQ Composite zum Ende des Dienstagshandels auf grünem Terrain

10.09.24

Pluszeichen in New York: Anleger lassen NASDAQ Composite am Nachmittag steigen

10.09.24

Schwacher Handel: So entwickelt sich der NASDAQ Composite aktuell

10.09.24

Freundlicher Handel: NASDAQ Composite startet im Plus

30.08.24

Börse New York in Grün: NASDAQ Composite beendet die Sitzung im Plus